| abstract |
The invention proposes the use of a selective COX-2 inhibitor and an HMG-CoA reductase inhibitor (a statin) to sensitize cancer cells or chemotherapy or radiopharmatherapy, and preferably a glutathione pathway enhancing and detoxifying compound such as cystine so that cancerous cells are more easily penetrated while normal cells are protected. Timing of therapy and methods are covered. |